Abstract
Chronic myeloid leukemia (CML) is induced by the BCR-ABL oncogene, a product of Philadelphia (Ph) chromosome. The BCR-ABL kinase inhibitor imatinib is a standard treatment for Ph+ leukemia, and has been shown to induce a complete hematologic and cytogenetic response in most chronic phrase CML patients. However, imatinib does not cure CML, and one of the reasons is that imatinib does not kill leukemia stem cells (LSCs) in CML both in vitro and in vivo. Recently, several new targets or drugs have been reported to inhibit LSCs in cultured human CD34+ CML cells or in mouse model of BCR-ABL induced CML, including an Alox5 pathway inhibitor, Hsp90 inhibitors, omacetaxine, hedgehog inhibitor and BMS-214662. Specific targeting of LSCs but not normal stem cell is a correct strategy for developing new anti-cancer therapies in the future.
Keywords: BCR-ABL, leukemic stem cells, CML, therapeutic agents
Anti-Cancer Agents in Medicinal Chemistry
Title: Novel Therapeutic Agents Against Cancer Stem Cells of Chronic Myeloid Leukemia
Volume: 10 Issue: 2
Author(s): Yaoyu Chen, Cong Peng, Con Sullivan, Dongguang Li and Shaoguang Li
Affiliation:
Keywords: BCR-ABL, leukemic stem cells, CML, therapeutic agents
Abstract: Chronic myeloid leukemia (CML) is induced by the BCR-ABL oncogene, a product of Philadelphia (Ph) chromosome. The BCR-ABL kinase inhibitor imatinib is a standard treatment for Ph+ leukemia, and has been shown to induce a complete hematologic and cytogenetic response in most chronic phrase CML patients. However, imatinib does not cure CML, and one of the reasons is that imatinib does not kill leukemia stem cells (LSCs) in CML both in vitro and in vivo. Recently, several new targets or drugs have been reported to inhibit LSCs in cultured human CD34+ CML cells or in mouse model of BCR-ABL induced CML, including an Alox5 pathway inhibitor, Hsp90 inhibitors, omacetaxine, hedgehog inhibitor and BMS-214662. Specific targeting of LSCs but not normal stem cell is a correct strategy for developing new anti-cancer therapies in the future.
Export Options
About this article
Cite this article as:
Chen Yaoyu, Peng Cong, Sullivan Con, Li Dongguang and Li Shaoguang, Novel Therapeutic Agents Against Cancer Stem Cells of Chronic Myeloid Leukemia, Anti-Cancer Agents in Medicinal Chemistry 2010; 10 (2) . https://dx.doi.org/10.2174/187152010790909326
DOI https://dx.doi.org/10.2174/187152010790909326 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
Call for Papers in Thematic Issues
Induction of cell death in cancer cells by modulating telomerase activity using small molecule drugs
Telomeres are distinctive but short stretches present at the corners of chromosomes and aid in stabilizing chromosomal makeup. Resynthesis of telomeres supported by the activity of reverse transcriptase ribonucleoprotein complex telomerase. There is no any telomerase activity in human somatic cells, but the stem cells and germ cells undergone telomerase ...read more
Role of natural compounds as anti anti-cancer agents
Cancer is considered the leading cause of worldwide mortality, accounting for nearly 10 million deaths in 2022. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy remains an important approach in treatment o f several types of cancers, even though ...read more
Signaling and enzymatic modulators in cancer treatment
Cancer accounts for nearly 10 million deaths in 2022 and is considered the leading cause of worldwide mortality. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy, radiotherapy and surgery are the most important approach for the treatment of several ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Eph/Ephrin Membrane Proteins: A Mammalian Expression Vector pTIg- BOS-Fc Allowing Rapid Protein Purification
Protein & Peptide Letters OX40 and OX40L Interaction in Cancer
Current Medicinal Chemistry Recent Developments of DNA Poisons - Human DNA Topoisomerase IIα Inhibitors - as Anticancer Agents
Current Pharmaceutical Design Modulation of Gene Transcription by Natural Products - A Viable Anticancer Strategy
Current Pharmaceutical Design Inhibitors of ABL and the ABL-T315I Mutation
Current Topics in Medicinal Chemistry Potassium Channels are a New Target Field in Anticancer Drug Design
Recent Patents on Anti-Cancer Drug Discovery Synthesis of Cis-Fused Pyran Indolocarbazole Derivatives that Inhibit FLT3 Kinase and the DNA Damage Kinase, Checkpoint Kinase 1
Anti-Cancer Agents in Medicinal Chemistry Self-Assembling Peptides: Potential Role in Tumor Targeting
Current Pharmaceutical Biotechnology Targeting Epigenetic Modifiers in Cancer
Current Medicinal Chemistry Association of p53 with Bid Induces Cell Death in Response to Etoposide Treatment in Hepatocellular Carcinoma
Current Cancer Drug Targets Insect Peptides – Perspectives in Human Diseases Treatment
Current Medicinal Chemistry A Long Time History of a Mediastinal Fibrosis with Triple Vascular Stenosis
Current Respiratory Medicine Reviews Signal Transduction Therapy with Rationally Designed Kinase Inhibitors
Current Signal Transduction Therapy EphA2-Dependent Molecular Targeting Therapy for Malignant Tumors
Current Cancer Drug Targets Beyond Single Pathway Inhibition: MEK Inhibitors as a Platform for the Development of Pharmacological Combinations with Synergistic Anti-Leukemic Effects
Current Pharmaceutical Design Polymorphisms of Human N-Acetyltransferases and Cancer Risk
Current Drug Metabolism The Design of Drug Candidate Molecules as Selective Inhibitors of Therapeutically Relevant Protein Kinases
Current Medicinal Chemistry LFA-1 on Leukemic Cells as a Target for Therapy or Drug Delivery
Current Pharmaceutical Design Medical and Dental Implications of Down Syndrome: A Review Part 1: General and Craniofacial Characteristic
Applied Clinical Research, Clinical Trials and Regulatory Affairs Promising Targets in Anti-cancer Drug Development: Recent Updates
Current Medicinal Chemistry